| P2093 | author name string | Constantine E Kosmas | |
| | Andreas Sourlas | |
| | Delia Silverio | |
| | Eliscer Guzman | |
| | Peter D Montan | |
| P2860 | cites work | Heart Failure with Preserved Ejection Fraction - Concept, Pathophysiology, Diagnosis and Challenges for Treatment | Q26747554 |
| | Effect of Mineralocorticoid Receptor Antagonists on Cardiac Structure and Function in Patients With Diastolic Dysfunction and Heart Failure With Preserved Ejection Fraction: A Meta-Analysis and Systematic Review | Q26783958 |
| | Heart failure with preserved ejection fraction: mechanisms, clinical features, and therapies | Q27000263 |
| | The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators | Q28372091 |
| | Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association | Q30238784 |
| | Prevention of aortic and cardiac fibrosis by spironolactone in old normotensive rats | Q32055195 |
| | Spironolactone for heart failure with preserved ejection fraction | Q34414462 |
| | Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment | Q34664894 |
| | Effects of mineralocorticoid receptor antagonists in patients with preserved ejection fraction: a meta-analysis of randomized clinical trials | Q35018046 |
| | Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic | Q35040738 |
| | Mineralocorticoid receptor antagonists for heart failure: systematic review and meta-analysis | Q36208986 |
| | Aldosterone and the risk of hypertension | Q36747846 |
| | The incidence and implications of aldosterone breakthrough | Q36918649 |
| | Left ventricular hypertrophy patterns and incidence of heart failure with preserved versus reduced ejection fraction | Q37434977 |
| | The progression of hypertensive heart disease | Q37832070 |
| | Vascular actions of aldosterone | Q38061580 |
| | Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial | Q38455453 |
| | Mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction (HFpEF). | Q38592650 |
| | Role of mineralocorticoid receptor activation in cardiac diastolic dysfunction | Q39042819 |
| | Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction: role of vascular superoxide anion formation and endothelial nitric oxide synthase expression | Q43852493 |
| | Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms | Q44272913 |
| | Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocard | Q44430971 |
| | Additive amelioration of left ventricular remodeling and molecular alterations by combined aldosterone and angiotensin receptor blockade after myocardial infarction | Q46539706 |
| | Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT Trial | Q48238085 |
| | Biological Phenotypes of Heart Failure With Preserved Ejection Fraction. | Q50098362 |
| | Serum aldosterone and its relationship to left ventricular structure and geometry in patients with preserved left ventricular ejection fraction. | Q51423999 |
| | Biomarker-based phenotyping of myocardial fibrosis identifies patients with heart failure with preserved ejection fraction resistant to the beneficial effects of spironolactone: results from the Aldo-DHF trial | Q52803941 |
| | Effect of Aldosterone Antagonism on Exercise Tolerance in Heart Failure With Preserved Ejection Fraction. | Q53563361 |
| | Limitation of Excessive Extracellular Matrix Turnover May Contribute to Survival Benefit of Spironolactone Therapy in Patients With Congestive Heart Failure | Q57259661 |
| | Aldosterone Receptor Blockade in Heart Failure with Preserved Ejection Fraction | Q91855803 |
| P433 | issue | 23 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | heart failure | Q181754 |
| | ejection fraction | Q641303 |
| | Heart failure with preserved ejection fraction | Q3799239 |
| P304 | page(s) | 461 | |
| P577 | publication date | 2018-12-01 | |
| P1433 | published in | Annals of Translational Medicine | Q26842362 |
| P1476 | title | Role of spironolactone in the treatment of heart failure with preserved ejection fraction | |
| P478 | volume | 6 | |